Climb Net Income from 2010 to 2026
| CLYM Stock | 5.44 0.79 16.99% |
Net Loss | First Reported 2020-03-31 | Previous Quarter -8.7 M | Current Value -12.9 M | Quarterly Volatility 11.2 M |
Check Climb Bio financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Climb Bio's main balance sheet or income statement drivers, such as Selling General Administrative of 13.8 M, Other Operating Expenses of 99 M or Research Development of 17 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.45. Climb financial statements analysis is a perfect complement when working with Climb Bio Valuation or Volatility modules.
Climb | Net Income | Build AI portfolio with Climb Stock |
Evaluating Climb Bio's Net Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Climb Bio's fundamental strength.
Latest Climb Bio's Net Income Growth Pattern
Below is the plot of the Net Income of Climb Bio over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Climb Bio financial statement analysis. It represents the amount of money remaining after all of Climb Bio operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Climb Bio's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Climb Bio's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (73.9 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Climb Net Income Regression Statistics
| Arithmetic Mean | (24,562,779) | |
| Coefficient Of Variation | (101.83) | |
| Mean Deviation | 21,653,243 | |
| Median | (6,547,000) | |
| Standard Deviation | 25,012,304 | |
| Sample Variance | 625.6T | |
| Range | 67.3M | |
| R-Value | (0.85) | |
| Mean Square Error | 180.8T | |
| R-Squared | 0.73 | |
| Significance | 0.000013 | |
| Slope | (4,229,389) | |
| Total Sum of Squares | 10009.8T |
Climb Net Income History
Other Fundumenentals of Climb Bio
About Climb Bio Financial Statements
Climb Bio investors utilize fundamental indicators, such as Net Income, to predict how Climb Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out the analysis of Climb Bio Correlation against competitors. To learn how to invest in Climb Stock, please use our How to Invest in Climb Bio guide.You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Will Biotechnology sector continue expanding? Could Climb diversify its offerings? Factors like these will boost the valuation of Climb Bio. Projected growth potential of Climb fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Climb Bio data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
The market value of Climb Bio is measured differently than its book value, which is the value of Climb that is recorded on the company's balance sheet. Investors also form their own opinion of Climb Bio's value that differs from its market value or its book value, called intrinsic value, which is Climb Bio's true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Climb Bio's market value can be influenced by many factors that don't directly affect Climb Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Climb Bio's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Climb Bio should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Climb Bio's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.